CATALYSTYahoo Finance • 1d ago
Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock?Yahoo Finance report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.
Why ALZN Stock surged +3.31% Today — RQD Quant Desk Flash
$1.25 +3.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.26
Alzamend Neuro Inc. (ALZN) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $6.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ALZN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ALZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Alzamend Neuro Inc. (NASDAQ: ALZN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.25 (+3.31% 1D, market cap $6.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ALZN ranks #655 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ALZN compare to BGMS and ACXP in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALZN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BGMS (Bio Green Med Solution Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $6.0M) and ACXP (Acurx Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $5.9M). Among the 5-stock peer group, ALZN leads on earnings multiple (N/A) while ALZN leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ALZN?
▼
Per ALZN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001677077), Alzamend Neuro Inc. generated $24.5M in revenue (+95.0% YoY), -$8.8M in net income, and -$8.1M in free cash flow against $4.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.26 (+0.41%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-11.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALZN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY ALZN SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.35-7.4% Next Q
42
Q2 (-2Q)Grade E$1.25-4.8% Next Q
39
Q3 (-1Q)Grade E$1.19+5% Next Q
37
CurrentGrade E$1.25-8.7% Hist 90D α
34
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ALZN Turnaround Squeeze
While ALZN currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.51) and Max Pain ($1.31) forces dealer call-delta covering toward $2.74.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALZN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ALZN Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ALZN Stock surged +3.31% Today — RQD Quant Desk Flash
Alzamend Neuro Inc. (ALZN) surged +3.31% to $1.25, trading at 23% of its 52-week range ($0.84 – $2.61). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 23% of its 52-week range ($0.84 – $2.61) with RSI-14 at 42.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.25 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ALZN Headlines & Catalysts
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
What Makes Allegion (ALLE) a New Buy StockYahoo Finance report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 2d ago
Complete U.S. Stocks List: Prices, Performance and Key DataTradingKey report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 2d ago
Alzamend Neuro (ALZN) Rises 4.26% to $1.34 as Shares Press Toward Range Resistance - Sector ETF Flowhttps://www.dars.gov.et/ report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 2d ago
ZenaTech, Inc. (ZENA) Upgraded to Buy: What Does It Mean for the Stock?Yahoo Finance report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 2d ago
Alpine Income (PINE) Upgraded to Strong Buy: Here's What You Should KnowYahoo Finance report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALZN)
- ✓Walkthrough of ALZN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ALZN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +16.82%📐 HORIZONTAL RANGE
2026-11-04O $1.21H $1.25L $1.21C $1.25VOL 37.1K
RES: $2.18SUP: $1.04SMA50: $1.51SMA200: $1.46
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ALZN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +95.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on ALZN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ALZN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ALZN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALZN)
Health Care Rank #655 of 1015
⚔️ BGMS vs ALZN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ALZN vs. BGMS, ACXP, APRE, SKYE)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Alzamend Neuro Inc. (ALZN) ranks #655 by composite RQD confidence (34/100, grade E) and #925 by equity capitalization ($6.0M). Within this direct 5-issuer industry benchmark cohort, ALZN leads on earnings valuation at N/A trailing P/E, while ALZN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APRE currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ALZN at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ALZN
ACTIVE
Alzamend Neuro Inc. | E | 34/100 | — | — | -35.0% | +3.31% | $6.0M | Benchmark Subject |
| BGMS Bio Green Med Solution Inc. | D- | 38/100 | — | — | -35.0% | 0.00% | $6.0M | /bgms-vs-alzn → |
| ACXP Acurx Pharmaceuticals Inc. | E | 33/100 | — | — | -35.0% | +2.89% | $5.9M | /acxp-vs-alzn → |
| APRE Aprea Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | +1.32% | $6.2M | /apre-vs-alzn → |
| SKYE Skye Bioscience Inc. | E | 34/100 | — | — | -35.0% | +3.13% | $5.8M | /skye-vs-alzn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2026-04-30 • CIK 0001677077 ↗In its most recent audited fiscal period (FY2025, filed 2026-04-30), Alzamend Neuro Inc. (ALZN) reported GAAP revenue of $24.5M (+95.0% vs. FY2024 revenue of $12.6M , and -11.8% cumulative change since FY2023) , GAAP net income of -$8.8M, operating cash flow of -$8.1M, and free cash flow of -$8.1M (-22.8% YoY). On the balance sheet, ALZN closed FY2025 with $4.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-04-30 | $24.5M | -$8.8M | -$8.1M | -$8.1M | $4.0M | — |
| FY2024 (FY) | 2025-04-30 | $12.6M | -$4.5M | -$6.6M | -$6.6M | $4.2M | — |
| FY2023 (FY) | 2024-04-30 | $27.8M | -$9.9M | -$8.3M | -$8.3M | — | — |
3. ALZN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ALZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Alzamend Neuro Inc. (NASDAQ: ALZN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.25 (+3.31% 1D, market cap $6.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ALZN ranks #655 in composite RQD confidence.
How does ALZN compare to BGMS and ACXP in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALZN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BGMS (Bio Green Med Solution Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $6.0M) and ACXP (Acurx Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $5.9M). Among the 5-stock peer group, ALZN leads on earnings multiple (N/A) while ALZN leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ALZN?
Per ALZN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001677077), Alzamend Neuro Inc. generated $24.5M in revenue (+95.0% YoY), -$8.8M in net income, and -$8.1M in free cash flow against $4.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ALZN trading relative to its 50-day, 200-day, and 52-week technical levels?
ALZN last traded at $1.25 (+3.31% on volume of 37,066 shares), positioning the stock -17.22% below its 50-day simple moving average ($1.51) and -14.38% below its 200-day simple moving average ($1.46). Across its 52-week range of $0.84 to $2.61, ALZN sits at the 23.2% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.09 to $1.41).
ROARABLE RATING BRIEF • RQD 34/100 (E)
✓ SEC XBRL & RQD VERIFIED
ALZN — Alzamend Neuro Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-04-30
1. Roarable Rating Brief: What This Means to a Prospective Investor
Alzamend Neuro Inc. (ALZN) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.25 (+3.31% 1D, market capitalization $6.0M).
- Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Alzamend Neuro Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It operates with a market capitalization of $0.0B. Products, customers, and revenue model are — Reported revenue is — across the periods provided.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-04-30), Alzamend Neuro Inc. (ALZN) reported $24.5M in annual revenue (up from $12.6M in FY2024, +95.0% YoY) and -$8.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($27.8M revenue, -$9.9M net income) through FY2025, ALZN scaled operating cash flow to -$8.1M and free cash flow to -$8.1M, backed by $4.0M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.84 – $2.61 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies: — Sector correlations beyond the Beta of 1.0 are — Investors should watch for disclosures on suppliers, partners, and clinical or licensing dependencies, none of which appear in the source data.
- Key Question #1: Can ALZN sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $24.5M and free cash flow of -$8.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is ALZN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
ALZN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Alzamend Neuro Inc. (ALZN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 1d ago
Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock? Yahoo Finance report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session Benzinga report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
What Makes Allegion (ALLE) a New Buy Stock Yahoo Finance report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 2d ago
Complete U.S. Stocks List: Prices, Performance and Key Data TradingKey report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 2d ago
Alzamend Neuro (ALZN) Rises 4.26% to $1.34 as Shares Press Toward Range Resistance - Sector ETF Flow https://www.dars.gov.et/ report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 2d ago
ZenaTech, Inc. (ZENA) Upgraded to Buy: What Does It Mean for the Stock? Yahoo Finance report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 2d ago
Alpine Income (PINE) Upgraded to Strong Buy: Here's What You Should Know Yahoo Finance report covering Alzamend Neuro Inc. (ALZN) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ALZN Bull vs. Bear Conversation Board — What's Your Call at $1.25?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALZN 🐻 33% BEARISH CONVICTION
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH
🎯 Target: $1.56 (+28.9%)
📌 Pinned Debate A reported upgrade to Buy and a 52-week low of $0.84 that sits well below the current $1.22 price suggest recent momentum.
The street is overcomplicating Alzamend Neuro Inc. (ALZN). A reported upgrade to Buy and a 52-week low of $0.84 that sits well below the current $1.22 price suggest recent momentum.. With an RQD score of 34/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.31.
VolSurface_Trader 🐂 BULL
Both sides have a point here — ALZN's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH
🎯 Target: $0.99 (-18.2%)
Spot @ $1.21 Negative ROIC of -35%, zero FCF yield, and a Piotroski F-Score of 1 out of 9 show the business consuming capital with a weak balance sh
Sitting on the sidelines or leaning short ALZN above $1.21. Negative ROIC of -35%, zero FCF yield, and a Piotroski F-Score of 1 out of 9 show the business consuming capital with a weak balance sheet.. Until Fundamental Cash Engine (8/20) and FCF yield (0.0%) inflect higher, upside is capped near $2.61.